ICLE 2022 | Developing individualized cancer therapies with neoantigen-specific TCRs

Angela Krackhard, MD, PhD, Technical University of Munich, Munich, Germany, provides an overview of targeting neoantigens specifically expressed on tumors with T-cell receptors (TCRs). Proteogenomic analysis consisting of deep sequencing analysis and mass spectrometry detected novel neoantigens and were validated with patient-derived T-cells. Further analysis revealed certain T-cell receptors that can be restimulated in a shorter amount of time as a result of a lower activation threshold. Prof. Krackhard also describes the differential transcription profile of these T-cells and other highly activated T-cells, as well as their therapeutic potential. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.